Metabolic imbalance and prostate cancer progression

International Journal of Molecular Epidemiology and Genetics

Volumn 1, Issue 4, 2010, Pages 248-271

  Burton, Anya J ^a   Tilling, Kate M ^a   Holly, Jeff M ^a   Hamdy, Freddie C ^b   Rowlands, Mari Anne E ^a   Donovan, Jenny L ^a   Martin, Richard M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adipokines; Diabetes; Inflammation; Insulin like growth factors; Metabolism; Obesity; Prostate cancer

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANDROGEN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 2 INHIBITOR; INSULIN; INTERLEUKIN 6; LEPTIN; LYCOPENE; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; SELENIUM; SEX HORMONE; SOMATOMEDIN C; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID METABOLISM; APOPTOSIS; ARTICLE; BODY MASS; CANCER GROWTH; CANCER INFILTRATION; CANCER RISK; CARCINOGENESIS; CELL CULTURE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHRONIC PROSTATITIS; ENVIRONMENTAL FACTOR; FATTY ACID SYNTHESIS; GENE MUTATION; GENETIC VARIABILITY; HORMONE SYNTHESIS; HYPERINSULINEMIA; INDUSTRIALIZATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID METABOLISM; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PROSTATE CANCER; SEXUALLY TRANSMITTED DISEASE; TESTOSTERONE BLOOD LEVEL; WEIGHT REDUCTION;

EID: 78449265759     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (176)

1. Owen DH and Katz DF. A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J Androl 2005; 26(4): 459-469.
2. Balk SP, Ko YJ, and Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003; 21(2): 383-391.
3. Krieger JN, Riley DE, Cheah PY, Liong ML, and Yuen KH. Epidemiology of prostatitis: new evidence for a world-wide problem. World Journal of Urology 2003; 21(2): 70-74.
4. Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol 2004; 6 Suppl 9: S3-S10.
5. Frankel S, Smith GD, Donovan J, and Neal D. Screening for prostate cancer. The Lancet 2003; 361(9363): 1122-1128.
6. McGregor M, Hanley JA, Boivin JF, and McLean RG. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 1998; 159(11): 1368-1372.
7. Ben-Shlomo Y, Evans S, Ibrahim F, Patel B, Anson K, Chinegwundoh F, Corbishley C, Dorling D, Thomas B, Gillatt D, Kirby R, Muir G, Nargund V, Popert R, Metcalfe C, and Persad R. The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS cohort study. Eur Urol 2008; 53(1): 99-105.
8. Hsing AW, Sakoda LC, and Chua SC, Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007; 86(3): 843S-8857.
9. Mistry T, Digby JE, Desai KM, and Randeva HS. Obesity and prostate cancer: a role for adipokines. Eur Urol 2007; 52(1): 46-53.
10. Freedland SJ and Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 2007; 29: 88-97.
11. Cordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, Watkins BA, O'Keefe JH, and Brand-Miller J. Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr 2005; 81(2): 341-354.
12. World Cancer Research Fund/American Institute for Cancer Research. Second Expert Report, Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective. 2007;
13. Simmons RK, Alberti KG, Gale EA, Colagiuri S, Tuomilehto J, Qiao Q, Ramachandran A, Tajima N, Brajkovich M, I, Ben-Nakhi A, Reaven G, Hama SB, Mendis S, and Roglic G. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010; 53(4): 600-605.
14. Haas GP, Delongchamps N, Brawley OW, Wang CY, and de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 2008; 15(1): 3866-3871.
15. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, and Tulinius H. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977; 20(5): 680-688.
16. Yatani R, Shiraishi T, Nakakuki K, Kusano I, Takanari H, Hayashi T, and Stemmermann GN. Trends in Frequency of Latent Prostate Carcinoma in Japan from 1965-1979 to 1982-1986. J Natl Cancer Inst 1988; 80(9): 683-687.
17. Peto J. Cancer epidemiology in the last century and the next decade. Nature 2001; 411 (6835): 390-395.
18. Iwasaki M, Mameri CP, Hamada GS, and Tsugane S. Cancer mortality among Japanese immigrants and their descendants in the state of Sao Paulo, Brazil, 1999-2001. Jpn J Clin Oncol 2004; 34(11): 673-680.
19. Lee J, Demissie K, Lu SE, and Rhoads GG. Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control 2007; 14(1): 78-85.
20. Rastogi T, Devesa S, Mangtani P, Mathew A, Cooper N, Kao R, and Sinha R. Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol 2008; 37(1): 147-160.
21. Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH, and Chen J. Changing trends of prostate cancer in Asia. Aging Male 2004; 7(2): 120-132.
22. Tominaga S and Kuroishi T. An ecological study on diet/nutrition and cancer in Japan. Int J Cancer 1997; Suppl 10: 2-6.
23. Renehan AG, Tyson M, Egger M, Heller RF, and Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371(9612): 569-578.
24. MacInnis RJ and English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006; 17(8): 989-1003.
25. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, Hurwitz P, Hollenbeck A, and Leitzmann MF. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109(4): 675-684.
26. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, Thun MJ, and Calle EE. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16(1): 63-69.
27. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, and Kristal AR. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiology, Biomarkers & Prevention 2006; 15(10): 1977-1983.
28. Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, and Gonzalgo ML. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology 2008; 72(6): 1246-1251.
29. Littman AJ, White E, and Kristal AR. Anthropometrics and prostate cancer risk. Am J Epidemiol 2007; 165(11): 1271-1279.
30. Wallstrom P, Bjartell A, Gullberg B, Olsson H, and Wirfalt E. A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. Br J Cancer 2009; 100 (11): 1799-1805.
31. Housa D, Housova J, Vernerova Z, and Haluzik M. Adipocytokines and cancer. Physiol Res 2006; 55(3): 233-244.
32. Onuma M, Bub JD, Rummel TL, and Iwamoto Y. Prostate Cancer Cell-Adipocyte Interaction: Leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 2003; 278 (43): 42660-42667.
33. Hoda MR and Popken G. Mitogenic and antiapoptotic actions of adipocyte-derived hormone leptin in prostate cancer cells. BJU Int 2008; 102(3): 383-388.
34. Frankenberry KA, Somasundar P, McFadden DW, and Vona-Davis LC. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg 2004; 188(5): 560-565.
35. Deo DD, Rao AP, Bose SS, Ouhtit A, Baliga SB, Rao SA, Trock BJ, Thouta R, Raj MH, and Rao PN. Differential effects of leptin on the invasive potential of androgen-dependent and - independent prostate carcinoma cells. J Biomed Biotechnol 2008; 2008: 163902
36. Mistry T, Digby JE, Desai KM, and Randeva HS. Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl-2 expression. BJU Int 2008; 101(10): 1317-1322.
37. Sierra-Honigmann MR, Nath AK, Murakami C, Garcí, a-Cardeñ, a G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, and Flores-Riveros JR. Biological Action of Leptin as an Angiogenic Factor. Science 1998; 281(5383): 1683-1686.
38. Culig Z, Steiner H, Bartsch G, and Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005; 95(3): 497-505.
39. Smith PC, Hobisch A, Lin DL, Culig Z, and Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001; 12(1): 33-40.
40. Wegiel B, Bjartell A, Culig Z, and Persson JL. Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer 2008; 122(7): 1521-1529.
41. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A, and Culig Z. Accelerated in Vivo Growth of Prostate Tumors that Up-Regulate Interleukin-6 Is Associated with Reduced Retinoblastoma Protein Expression and Activation of the Mitogen-Activated Protein Kinase Pathway. Am J Pathol 2003; 162(2): 655-663.
42. Bub JD, Miyazaki T, and Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochemical and Biophysical Research Communications 2006; 340(4): 1158-1166.
43. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, and Cao Y. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004; 101(8): 2476-2481.
44. Baillargeon J and Rose DP. Obesity, adipokines, and prostate cancer (review). Int J Oncol 2006; 28(3): 737-745.
45. Kelesidis I, Kelesidis T, and Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer 2006; 94(9): 1221-1225.
46. Barb D, Williams CJ, Neuwirth AK, and Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 2007; 86(3): s858-s866.
47. Frankel S, Gunnell DJ, Peters TJ, Maynard M, and Smith GD. Childhood energy intake and adult mortality from cancer: the boyd orr cohort study. BMJ 1998; 316(7130): 499-504.
48. Stocks T, Lukanova A, Rinaldi S, Biessy C, Dossus L, Lindahl B, Hallmans G, Kaaks R, and Stattin P. Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer 2007; 120 (12): 2678-2686.
49. Saglam K, Aydur E, Yilmaz M, and Goktas S. Leptin influences cellular differentiation and progression in prostate cancer. J Urol 2003; 169(4): 1308-1311.
50. Stattin P, Soderberg S, Hallmans G, Bylund A, Kaaks R, Stenman UH, Bergh A, and Olsson T. Leptin Is Associated with Increased Prostate Cancer Risk: A Nested Case-Referent Study. J Clin Endocrinol Metab 2001; 86(3): 1341-1345.
51. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, and Ma J. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 2010; 56(1): 34-43.
52. Stattin P, Kaaks R, Johansson R, Gislefoss R, Soderberg S, Alfthan H, Stenman UH, Jellum E, and Olsson T. Plasma Leptin Is Not Associated with Prostate Cancer Risk. Cancer Epidemiol Biomarkers Prev 2003; 12(5): 474-475.
53. Hsing AW, Chua S Jr, Gao YT, Gentzschein E, Chang L, Deng J, and Stanczyk FZ. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001; 93(10): 783-789.
54. Parekh DJ, Ankerst DP, Baillargeon J, Higgins B, Platz EA, Troyer D, Hernandez J, Leach RJ, Lokshin A, and Thompson IM. Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Cancer Epidemiol Biomarkers Prev 2007; 16(10): 1966-1972.
55. Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, Higgins B, Lokshin A, Troyer D, Hernandez J, Lynch S, Leach RJ, and Thompson IM. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev 2006; 15(7): 1331-1335.
56. Lagiou P, Signorello LB, Trichopoulos D, Tzonou A, Trichopoulou A, and Mantzoros CS. Leptin in relation to prostate cancer and benign prostatic hyperplasia. Int J Cancer 1998; 76(1): 25-28.
57. Arisan ED, Arisan S, Atis G, Palavan-Unsal N, and Ergenekon E. Serum adipocytokine levels in prostate cancer patients. Urol Int 2009; 82 (2): 203-208.
58. Neuhouser ML, Till C, Kristal A, Goodman P, Hoque A, Platz EA, Hsing AW, Albanes D, Parnes HL, and Pollak M. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila Pa) 2010; 3(3): 279-289.
59. Chang S, Hursting SD, Contois JH, Strom SS, Yamamura Y, Babaian RJ, Troncoso P, Scardino PS, Wheeler TM, Amos CI, and Spitz MR. Leptin and prostate cancer. Prostate 2001; 46(1): 62-67.
60. Moore SC, Leitzmann MF, Albanes D, Weinstein SJ, Snyder K, Virtamo J, Ahn J, Mayne ST, Yu H, Peters U, and Gunter MJ. Adipokine genes and prostate cancer risk. Int J Cancer 2009; 124(4): 869-876.
61. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, and Bedir S. Prostate cancer and adiponectin. Urology 2005; 65(6): 1168-1172.
62. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, and Mantzoros CS. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev 2007; 16 (2): 308-313.
63. Housa D, Vernerova Z, Heracek J, Prochazka B, Cechak P, Kuncova J, and Haluzik M. Adiponectin as a potential marker of prostate cancer progression: studies in organ-confined and locally advanced prostate cancer. Physiol Res 2008; 57(3): 451-458.
64. Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS, and Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. Prostate 2008; 68(14): 1592-1598.
65. Freedland SJ, Sokoll LJ, Platz EA, Mangold LA, Bruzek DJ, Mohr P, Yiu SK, and Partin AW. Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol 2005; 174(4 Pt 1): 1266-1270.
66. Tokuda Y, Satoh Y, Fujiyama C, Toda S, Sugihara H, and Masaki Z. Prostate cancer cell growth is modulated by adipocyte-cancer cell interaction. BJU Int 2003; 91(7): 716-720.
67. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444(7121): 860-867.
68. Lehrke M and Lazar MA. Inflamed about obesity. Nat Med 2004; 10(2): 126-127.
69. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004; 15(11): 2792-2800.
70. Mena S, Ortega A, and Estrela JM. Oxidative stress in environmental-induced carcinogenesis. Mutat Res 2009; 674(1-2): 36-44.
71. Nunez C, Cansino JR, Bethencourt F, Perez-Utrilla M, Fraile B, Martinez-Onsurbe P, Olmedilla G, Paniagua R, and Royuela M. TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma). Histopathology 2008; 53(2): 166-176.
72. Ricote M, Garcia-Tunon I, Bethencourt FR, Fraile B, Paniagua R, and Royuela M. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 2004; 100(7): 1388-1396.
73. Bouraoui Y, Ricote M, Garcia-Tunon I, Rodriguez-Berriguete G, Touffehi M, Rais NB, Fraile B, Paniagua R, Oueslati R, and Royuela M. Proinflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer. Cancer Detect Prev 2008; 32(1): 23-32.
74. Kundu JK and Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res 2008; 659(1-2): 15-30.
75. Maitland NJ and Collins AT. Inflammation as the primary aetiological agent of human prostate cancer: a stem cell connection? J Cell Biochem 2008; 105(4): 931-939.
76. Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, and Slawin KM. Association of Preoperative Plasma Levels of Vascular Endothelial Growth Factor and Soluble Vascular Cell Adhesion Molecule-1 With Lymph Node Status and Biochemical Progression After Radical Prostatectomy. J Clin Oncol 2004; 22 (9): 1655-1663.
77. Michalaki V, Syrigos K, Charles P, and Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004; 90(12): 2312-2316.
78. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, and Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001; 58(6): 1008-1015.
79. Svatek RS, Jeldres C, Karakiewicz PI, Suardi N, Walz J, Roehrborn CG, Montorsi F, Slawin KM, and Shariat SF. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 2009; 69(8): 886-894.
80. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D, and Parker C. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008; 9(4): 342-351.
81. Oh BR, Sasaki M, Perinchery G, Ryu SB, Park YI, Carroll P, and Dahiya R. Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol 2000; 163(5): 1584-1587.
82. Saenz-Lopez P, Carretero R, Cozar JM, Romero JM, Canton J, Vilchez JR, Tallada M, Garrido F, and Ruiz-Cabello F. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer 2008; 8: 382
83. Sun J, Turner A, Xu J, Gronberg H, and Isaacs W. Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol 2007; 25(3): 250-259.
84. Pierce BL, Biggs ML, DeCambre M, Reiner AP, Li C, Fitzpatrick A, Carlson CS, Stanford JL, and Austin MA. C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control 2009; 20(7): 1193-1203.
85. Platz EA and Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. The Journal of Steroid Bio-chemistry and Molecular Biology 2004; 92(4): 237-253.
86. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, and Coltman CA, Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349(3): 215-224.
87. Roddam AW, Allen NE, Appleby P, Key TJ, and Prostate Cancer Collaborative Grou. Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies. J Natl Cancer Inst 2008; 100(3): 170-183.
88. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, and Rittmaster RS. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362(13): 1192-1202.
89. Kaaks R, Lukanova A, Rinaldi S, Biessy C, Soderberg S, Olsson T, Stenman UH, Riboli E, Hallmans G, and Stattin P. Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 2003; 12(4): 309-315.
90. Kaaks R and Stattin P. Obesity, endogenous hormone metabolism, and prostate cancer risk: a conundrum of highs and lows. Cancer Prev Res (Phila Pa) 2010; 3(3): 259-262.
91. Calton BA, Chang SC, Wright ME, Kipnis V, Lawson K, Thompson FE, Subar AF, Mouw T, Campbell DS, Hurwitz P, Hollenbeck A, Schatzkin A, and Leitzmann MF. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 2007; 18(5): 493-503.
92. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, and Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005; 161(2): 147-152.
93. Kasper JS and Giovannucci E. A Meta-analysis of Diabetes Mellitus and the Risk of Prostate Cancer. Cancer Epidemiol Biomarkers Prev 2006; 15(11): 2056-2062.
94. Barnard RJ, Aronson WJ, Tymchuk CN, and Ngo TH. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev 2002; 3(4): 303-308.
95. Lehrer S, Diamond EJ, Stagger S, Stone NN, and Stock RG. Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate 2002; 50(1): 1-3.
96. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, and Stampfer MJ. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008; 9(11): 1039-1047.
97. Turner E, Lane A, Donovan J, Davis M, Metcalfe C, Neal D, Hamdy F, and Martin RM. Association of diabetes mellitus with prostate cancer: Nested case-control study (ProtecT: Prostate testing for cancer and treatment). Int J Cancer 2010; In press
98. Baradaran N, Ahmadi H, Salem S, Lotfi M, Jahani Y, Baradaran N, Mehrsai AR, and Pourmand G. The protective effect of diabetes mellitus against prostate cancer: Role of sex hormones. Prostate 2009; 69(16): 1744-1750.
99. Murad A, Davey Smith G, Lewis S, Cox A, Donovan J, Neal D, Hamdy F, and Martin RM. A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case control study (the ProtecT study). International Journal of Molecular Epidemiology and Genetics 2010; 1(3): 175-183.
100. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Blondal T, Stacey SN, Helgason A, Gunnarsdottir S, Olafsdottir A, Kristinsson KT, Birgisdottir B, Ghosh S, Thorlacius S, Magnusdottir D, Stefansdottir G, Kristjansson K, Bagger Y, Wilensky RL, Reilly MP, Morris AD, Kimber CH, Adeyemo A, Chen Y, Zhou J, So WY, Tong PC, Ng MC, Hansen T, Andersen G, Borch-Johnsen K, Jorgensen T, Tres A, Fuertes F, Ruiz-Echarri M, Asin L, Saez B, van BE, Klaver S, Swinkels DW, Aben KK, Graif T, Cashy J, Suarez BK, van Vierssen TO, Frigge ML, Ober C, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Palmer CN, Rotimi C, Chan JC, Pedersen O, Sigurdsson G, Benediktsson R, Jonsson E, Einarsson GV, Mayordomo JI, Catalona WJ, Kiemeney LA, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, and Stefansson K. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39(8): 977-983.
101. McKeehan WL, Adams PS, and Rosser MP. Direct Mitogenic Effects of Insulin, Epidermal Growth Factor, Glucocorticoid, Cholera Toxin, Unknown Pituitary Factors and Possibly Prolactin, but not Androgen, on Normal Rat Prostate Epithelial Cells in Serum-free, Primary Cell Culture. Cancer Res 1984; 44(5): 1998-2010.
102. Polychronakos C, Janthly U, Lehoux JG, and Koutsilieris M. Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved. Prostate 1991; 19(4): 313-321.
103. Cohen P, Peehl DM, Lamson G, and Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991; 73(2): 401-407.
104. Gennigens C, Menetrier-Caux C, and Droz JP. Insulin-Like Growth Factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006; 58(2): 124-145.
105. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8(12): 915-928.
106. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, and Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002; 62(10): 2942-2950.
107. Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, and Pollak M. Insulin receptor expression by human prostate cancers. Prostate 2009; 69(1): 33-40.
108. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, and Martin RM. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 2009; 124(10): 2416-2429.
109. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV, Jr., Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schroder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP, Jr., Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, and Galan P. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008; 149(7): 461-468.
110. Zuccolo L, Harris R, Gunnell D, Oliver S, Lane JA, Davis M, Donovan J, Neal D, Hamdy F, Beynon R, Savovic J, and Martin RM. Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. Cancer Epidemiol Biomarkers Prev 2008; 17 (9): 2325-2336.
111. Gunnell D, Oliver SE, Peters TJ, Donovan JL, Persad R, Maynard M, Gillatt D, Pearce A, Hamdy FC, Neal DE, and Holly JM. Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. Br J Cancer 2003; 88(11): 1682-1686.
112. Kojima S, Inahara M, Suzuki H, Ichikawa T, and Furuya Y. Implications of insulin-like growth factor-I for prostate cancer therapies. Int J Urol 2009; 16(2): 161-167.
113. Meinbach DS and Lokeshwar BL. Insulin-like growth factors and their binding proteins in prostate cancer: Cause or consequence? Urologic Oncology: Seminars and Original Investigations 2007; 24(4): 294-306.
114. van der Poel HG. Molecular markers in the diagnosis of prostate cancer. Crit Rev Oncol Hematol 2007; 61(2): 104-139.
115. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, and Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59(17): 4291-4296.
116. Koksal IT, Dirice E, Yasar D, Sanlioglu AD, Ciftcioglu A, Gulkesen KH, Ozes NO, Baykara M, Luleci G, and Sanlioglu S. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol Oncol 2004; 22(4): 307-312.
117. Martin RM, Holly JM, Davey SG, and Gunnell D. Associations of adiposity from childhood into adulthood with insulin resistance and the insulin-like growth factor system: 65-year follow-up of the Boyd Orr Cohort. J Clin Endocrinol Metab 2006; 91(9): 3287-3295.
118. Degraff DJ, Aguiar AA, and Sikes RA. Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am J Transl Res 2009; 1(2): 115-130.
119. Perks CM, Vernon EG, Rosendahl AH, Tonge D, and Holly JM. IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 2007; 26(40): 5966-5972.
120. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, and Rosenfeld RG. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993; 76(4): 1031-1035.
121. Ho PJ and Baxter RC. Insulin-like growth factor -binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf) 1997; 46(3): 333-342.
122. Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM, and Slawin KM. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 2002; 20(3): 833-841.
123. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, and Karasik A. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993; 77(1): 229-233.
124. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, and Kaaks R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000; 92(23): 1910-1917.
125. Oliver SE, Gunnell D, Donovan J, Peters TJ, Persad R, Gillatt D, Pearce A, Neal DE, Hamdy FC, and Holly J. Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. Int J Cancer 2004; 108(6): 887-892.
126. Inman BA, Harel F, Audet JF, Meyer F, Douville P, Fradet Y, and Lacombe L. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. Eur Urol 2005; 47(5): 695-702.
127. Moore MG, Wetterau LA, Francis MJ, Peehl DM, and Cohen P. Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer 2003; 105(1): 14-19.
128. Levitt RJ, Georgescu MM, and Pollak M. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem Biophys Res Commun 2005; 336(4): 1056-1061.
129. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, and Sawyers CL. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 2007; 104(13): 5563-5568.
130. Wright J and Stanford J. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes and Control 2009; 20(9): 1617-1622.
131. Sandoval DA and Davis SN. Leptin: metabolic control and regulation. J Diabetes Complications 2003; 17(2): 108-113.
132. Fradet V, Cheng I, Casey G, and Witte JS. Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res 2009; 15(7): 2559-2566.
133. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006; 83(6 Suppl): 1505S-1519S.
134. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, and Loda M. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 2009; 101(7): 519-532.
135. Locke JA, Guns ES, Lehman ML, Ettinger S, Zoubeidi A, Lubik A, Margiotti K, Fazli L, Adomat H, Wasan KM, Gleave ME, and Nelson CC. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate 2009; 70(3): 239-251.
136. Tennant DA, Duran RV, and Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010; 10(4): 267-277.
137. Browning DR and Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007; 120(4): 833-843.
138. Kuoppala J, Lamminpaa A, and Pukkala E. Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 2008; 44(15): 2122-2132.
139. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, and Giovannucci E. Statin Drugs and Risk of Advanced Prostate Cancer. J Natl Cancer Inst 2006; 98(24): 1819-1825.
140. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, and Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457(7231): 910-914.
141. Huang YC, Lee CM, Chen M, Chung MY, Chang YH, Huang WJ, Ho DM, Pan CC, Wu TT, Yang S, Lin MW, Hsieh JT, and Chen YM. Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin Cancer Res 2007; 13(5): 1412-1420.
142. Abate-Shen C and Shen MM. Diagnostics: The prostate-cancer metabolome. Nature 2009; 457(7231): 799-800.
143. Nelson WG, De Marzo AM, and Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology 2009; 150 (9): 3991-4002.
144. Kang GH, Lee S, Lee HJ, and Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intra-epithelial neoplasia. J Pathol 2004; 202(2): 233-240.
145. Phe V, Cussenot O, and Roupret M. Methylated genes as potential biomarkers in prostate cancer. BJU Int 2010;
146. Li LC, Carroll PR, and Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005; 97(2): 103-115.
147. Shi XB, Tepper CG, and White RW. MicroRNAs and prostate cancer. J Cell Mol Med 2008; 12 (5A): 1456-1465.
148. Saini S, Majid S, and Dahiya R. Diet, microRNAs and prostate cancer. Pharm Res 2010; 27(6): 1014-1026.
149. Dennis LK, Lynch CF, and Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002; 60(1): 78-83.
150. Daniels NA, Ewing SK, Zmuda JM, Wilt TJ, and Bauer DC. Correlates and prevalence of prostatitis in a large community-based cohort of older men. Urology 2005; 66(5): 964-970.
151. Nelson WG, De Marzo AM, and Isaacs WB. Prostate cancer. N Engl J Med 2003; 349(4): 366-381.
152. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, and Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431(7007): 461-466.
153. Aggarwal BB, Vijayalekshmi RV, and Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009; 15(2): 425-430.
154. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, and Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7(4): 256-269.
155. Nelson WG, DeWeese TL, and DeMarzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002; 21(1): 3-16.
156. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB, and Nelson WG. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004; 91(3): 459-477.
157. Wagenlehner FM, Elkahwaji JE, Algaba F, Bjerklund-Johansen T, Naber KG, Hartung R, and Weidner W. The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU Int 2007; 100(4): 733-737.
158. De Marzo AM, Nakai Y, and Nelson WG. Inflammation, atrophy, and prostate carcinogenesis. Urol Oncol 2007; 25(5): 398-400.
159. De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, and Nelson WG. Human prostate cancer precursors and pathobiology. Urology 2003; 62(5 Suppl 1): 55-62.
160. El-Omar EM, Ng MT, and Hold GL. Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 2008; 27(2): 244-252.
161. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, and Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99(8): 608-615.
162. James N. Cyclooxygenase-2 inhibitors and prostate cancer. Lancet Oncol 2007; 8(10): 859-860.
163. Cai Y, Lee YF, Li G, Liu S, Bao BY, Huang J, Hsu CL, and Chang C. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. Int J Cancer 2008; 123(1): 195-201.
164. Murad A, Down L, Davey Smith G, Donovan J, Lane A, Hamdy F, Neal D, and Martin RM. Associations of asprins, non-steroidal anti-inflammatory drug and paracetomol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). International Journal of Cancer 2010; In press
165. Adams TD, Stroup AM, Gress RE, Adams KF, Calle EE, Smith SC, Halverson RC, Simper SC, Hopkins PN, and Hunt SC. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring) 2009; 17(4): 796-802.
166. Renehan AG, Frystyk J, and Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006; 17(8): 328-336.
167. Gunnell D, Oliver SE, Donovan JL, Peters TJ, Gillatt D, Persad R, Hamdy FC, Neal DE, and Holly JM. Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease? J Clin Endocrinol Metab 2004; 89(1): 213-218.
168. Gunnell D, Miller LL, Rogers I, and Holly JM. Association of insulin-like growth factor I and insulin-like growth factor-binding protein-3 with intelligence quotient among 8- to 9-year-old children in the Avon Longitudinal Study of Parents and Children. Pediatrics 2005; 116 (5): e681-e686.
169. Ferrucci L, Cherubini A, Bandinelli S, Bartali B, Corsi A, Lauretani F, Martin A, Andres-Lacueva C, Senin U, and Guralnik JM. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 2006; 91(2): 439-446.
170. Aronson WJ, Barnard RJ, Freedland SJ, Henning S, Elashoff D, Jardack PM, Cohen P, Heber D, and Kobayashi N. Growth Inhibitory Effect of Low Fat Diet on Prostate Cancer Cells: Results of a Prospective, Randomized Dietary Intervention Trial in Men With Prostate Cancer. The Journal of Urology 2010; 183(1): 345-350.
171. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, III, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Jr., Baker LH, and Coltman CA, Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301(1): 39-51.
172. Thomas DC and Conti DV. Commentary: the concept of 'Mendelian Randomization'. Int J Epidemiol 2004; 33(1): 21-25.
173. Smith GD and Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004; 33(1): 30-42.
174. Ebrahim S and Davey SG. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet 2008; 123(1): 15-33.
175. Hoffstedt J, Eriksson P, Mottagui-Tabar S, and Arner P. A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin. Horm Metab Res 2002; 34(7): 355-359.
176. Ribeiro R, Vasconcelos A, Costa S, Pinto D, Morais A, Oliveira J, Lobo F, Lopes C, and Medeiros R. Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate 2004; 59(3): 268-274.